{"id":"W4405035264","doi":"10.1182/blood-2024-198737","title":"CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Obinutuzumab; Venetoclax; Ibrutinib; Medicine; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004897895,0.0005138147,0.00103905,0.0002644541,0.0002105184,0.0002019096,0.0007160849,0.0002283697,0.0001866436],"category_scores_gemma":[0.0002476554,0.0004268202,0.0001826191,0.0005216461,0.0002065876,0.0002961249,0.0003087542,0.0002234742,0.00007848621],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01151897,"about_ca_system_score_gemma":0.02146149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004700256,"about_ca_topic_score_gemma":0.0004307934,"domain_scores_codex":[0.9961626,0.0001730795,0.0008060486,0.001168315,0.0008394502,0.0008505067],"domain_scores_gemma":[0.997177,0.0005887661,0.00017347,0.001232915,0.0003142963,0.0005135186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.07585504,0.3504941,0.002314742,0.01156528,0.02565111,0.02217793,0.06735723,0.0006157572,0.1794714,0.004760212,0.06056347,0.1991737],"study_design_scores_gemma":[0.7212353,0.09415423,0.0001852141,0.001235874,0.003243048,0.000964938,0.002616332,0.07280334,0.05140782,0.0002240397,0.05096877,0.0009610716],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847994,0.0009781615,0.00005060994,0.0001199612,0.0002629212,0.01267841,0.0002185145,0.0002226569,0.0006693874],"genre_scores_gemma":[0.9906703,0.0001071656,0.001814132,0.00009605816,0.0007019475,0.003224045,0.0003084459,0.0001733236,0.002904586],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6453803,"threshold_uncertainty_score":0.9998184,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1274173297696315,"score_gpt":0.445436246826477,"score_spread":0.3180189170568455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}